Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that 2,500,000 options ("Options") over the ordinary shares of 1p each in the share capital of the Company ("Ordinary Shares") were granted to Directors and Persons Discharging Managerial Responsibilities on 10 July 2019.
The Options, which will vest in three equal tranches over three years, have an exercise period of ten years from grant and have an exercise price per Option of 3.85p. The Options vest in full upon the closing middle market price per Ordinary Share achieving 10p and positive cash flows from operations being sustained for any period of six months following date of grant.
Shares options granted
Chief Business Officer
PDMR / VP Tissue Products
PDMR / VP Global R&D
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities / person closely associated
1. Lou Ruggiero
2. Kevin Darling
3. Christian Wattengel
Reason for the notification
1. Chief Business Officer
2. PDMR / VP Tissue Products
3. PDMR / VP Global R&D
Initial notification /Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Collagen Solutions plc
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Ordinary shares of 1p each
ISIN Code: GB00B94T6Y14
Nature of the transaction
Grant of options over ordinary shares of 1p each exercisable at 3.85p
Price(s) and volume(s)
1. 0p per share
2. 0p per share
3. 0p per share
- Aggregated volume
Date of the transaction
10 July 2019
Place of the transaction
Outside a trading venue
Collagen Solutions Plc
Contact via Walbrook
Jamal Rushdy, Chief Executive Officer
Hilary Spence, Chief Financial Officer
Cenkos Securities plc (Nominated Adviser and Broker)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Collagen Solutions (LON: COS) CEO Jamal Rushdy joined Steve Darling from Proactive to discuss the company releasing their financial numbers that show impressive double-digit sales growth.
Rushdy talks about the numbers and also their tissue division that continues to be a revenue driver.